Miller Lauren E, Au Vivienne, Mokhtari Tara E, Goss Deborah, Faden Daniel L, Varvares Mark A
Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear, Boston, MA 02114, USA.
Cancers (Basel). 2022 Feb 16;14(4):992. doi: 10.3390/cancers14040992.
ACC is a rare malignant tumor of the salivary glands. In this contemporary review, we explore advances in identification of targetable alterations and clinical trials testing these druggable targets. A search of relevant articles and abstracts from national meetings and three databases, including PubMed, Medline, and Web of Science, was performed. Following keyword search analysis and double peer review of abstracts to ensure appropriate fit, a total of 55 manuscripts were included in this review detailing advances in molecular targets for ACC. The most researched pathway associated with ACC is the MYB-NFIB translocation, found to lead to dysregulation of critical cellular pathways and thought to be a fundamental driver in a subset of ACC disease pathogenesis. Other notable molecular targets that have been studied include the cKIT receptor, the EGFR pathway, and NOTCH1, all with limited efficacy in clinical trials. The ongoing investigation of molecular abnormalities underpinning ACC that may be responsible for carcinogenesis is critical to identifying and developing novel targeted therapies.
腺样囊性癌是一种罕见的唾液腺恶性肿瘤。在这篇当代综述中,我们探讨了可靶向改变的识别进展以及针对这些可药物化靶点的临床试验。我们检索了来自全国性会议以及三个数据库(包括PubMed、Medline和Web of Science)的相关文章和摘要。经过关键词搜索分析以及对摘要进行双盲同行评审以确保合适性后,本综述共纳入了55篇详细阐述腺样囊性癌分子靶点进展的手稿。与腺样囊性癌相关研究最多的途径是MYB-NFIB易位,该易位被发现会导致关键细胞途径失调,并被认为是一部分腺样囊性癌疾病发病机制的根本驱动因素。其他已研究的显著分子靶点包括cKIT受体、EGFR途径和NOTCH1,它们在临床试验中的疗效均有限。对可能导致腺样囊性癌发生的分子异常进行持续研究对于识别和开发新型靶向治疗至关重要。